Combined Tumor-Based IBRCA1/2/I and ITP53/I Mutation Testing in Ovarian Cancer
Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2023-07, Vol.24 (14) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 14 |
| container_start_page | |
| container_title | International journal of molecular sciences |
| container_volume | 24 |
| creator | Borcoman, Edith Santana dos Santos, Elizabeth Genestie, Catherine Pautier, Patricia Lacroix, Ludovic Caputo, Sandrine M Cabaret, Odile Guillaud-Bataille, Marine Michels, Judith Auguste, Aurelie Leary, Alexandra Rouleau, Etienne |
| description | Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP53m) may improve the quality of results in somatic BRCAm identification and interpretation of the ‘second hit’ event, i.e., loss of heterozygosity (LOH). A total of 237 patients with HGSOC underwent tBRCA/TP53m testing. The ratio of allelic fractions (AFs) for tBRCA/TP53m was calculated to estimate the proportion of cells carrying BRCAm and to infer LOH. Among the 142/237 gBRCA results, 16.2% demonstrated a pathogenic/deleterious variant (DEL) gBRCA1/2m. Among the 195 contributive tumor samples, 43 DEL of tBRCAm (22.1%) were identified (23 gBRCAm and 20 sBRCAm) with LOH identified in 37/41 conclusive samples. The median AF of TP53m was 0.52 (0.01–0.93), confirming huge variability in tumor cellularity. Initially, three samples were considered as wild type with |
| doi_str_mv | 10.3390/ijms241411570 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A759152938</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A759152938</galeid><sourcerecordid>A759152938</sourcerecordid><originalsourceid>FETCH-LOGICAL-g678-6d5ac3e38d2928c41157c02fa635c2637aad244acb8d43ac9f81a1cf010f49503</originalsourceid><addsrcrecordid>eNptjr1PwzAQxT2ARCmM7JaY0_gzscc2AhqpUISyV1d_RK4aR4pT_n4sYGBAN9zvnd57OoQeKFlxrkkZTkNiggpKZU2u0IIKxgpCqvoG3aZ0IoRxJvUCvTXjcAzRWdxdhnEqNpAyt5uPZk1LVrYYYpbdu-SZXy8zzGGMuHNpDrHHIeL9J0wBIm4gGjfdoWsP5-Tuf_cSdc9PXbMtdvuXtlnvir6qVVFZCYY7rizTTJnvJw1hHiouDat4DWCZEGCOygoORntFgRpPKPFCS8KX6PGntoezO4Tox3kCM4RkDutaaiqZ5iq7Vv-48lg3BDNG50O-_wl8AQkBWns</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combined Tumor-Based IBRCA1/2/I and ITP53/I Mutation Testing in Ovarian Cancer</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Borcoman, Edith ; Santana dos Santos, Elizabeth ; Genestie, Catherine ; Pautier, Patricia ; Lacroix, Ludovic ; Caputo, Sandrine M ; Cabaret, Odile ; Guillaud-Bataille, Marine ; Michels, Judith ; Auguste, Aurelie ; Leary, Alexandra ; Rouleau, Etienne</creator><creatorcontrib>Borcoman, Edith ; Santana dos Santos, Elizabeth ; Genestie, Catherine ; Pautier, Patricia ; Lacroix, Ludovic ; Caputo, Sandrine M ; Cabaret, Odile ; Guillaud-Bataille, Marine ; Michels, Judith ; Auguste, Aurelie ; Leary, Alexandra ; Rouleau, Etienne</creatorcontrib><description>Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP53m) may improve the quality of results in somatic BRCAm identification and interpretation of the ‘second hit’ event, i.e., loss of heterozygosity (LOH). A total of 237 patients with HGSOC underwent tBRCA/TP53m testing. The ratio of allelic fractions (AFs) for tBRCA/TP53m was calculated to estimate the proportion of cells carrying BRCAm and to infer LOH. Among the 142/237 gBRCA results, 16.2% demonstrated a pathogenic/deleterious variant (DEL) gBRCA1/2m. Among the 195 contributive tumor samples, 43 DEL of tBRCAm (22.1%) were identified (23 gBRCAm and 20 sBRCAm) with LOH identified in 37/41 conclusive samples. The median AF of TP53m was 0.52 (0.01–0.93), confirming huge variability in tumor cellularity. Initially, three samples were considered as wild type with <10% cellularity. However, additional testing detected a very low AF (<0.05) in both BRCA1/2m and TP53m, thus reidentifying them as sBRCA1/2m. Combined tBRCA/TP53m testing is rapid, sensitive, and identifies somatic and germline BRCA1/2m. AF TP53m is essential for interpreting sBRCA1/2m in low-cellularity samples and provides indirect evidence for LOH as the ‘second hit’ of BRCA1/2-related tumorigenesis.</description><identifier>ISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms241411570</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Medical tests ; Ovarian cancer ; Tumor proteins</subject><ispartof>International journal of molecular sciences, 2023-07, Vol.24 (14)</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Borcoman, Edith</creatorcontrib><creatorcontrib>Santana dos Santos, Elizabeth</creatorcontrib><creatorcontrib>Genestie, Catherine</creatorcontrib><creatorcontrib>Pautier, Patricia</creatorcontrib><creatorcontrib>Lacroix, Ludovic</creatorcontrib><creatorcontrib>Caputo, Sandrine M</creatorcontrib><creatorcontrib>Cabaret, Odile</creatorcontrib><creatorcontrib>Guillaud-Bataille, Marine</creatorcontrib><creatorcontrib>Michels, Judith</creatorcontrib><creatorcontrib>Auguste, Aurelie</creatorcontrib><creatorcontrib>Leary, Alexandra</creatorcontrib><creatorcontrib>Rouleau, Etienne</creatorcontrib><title>Combined Tumor-Based IBRCA1/2/I and ITP53/I Mutation Testing in Ovarian Cancer</title><title>International journal of molecular sciences</title><description>Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP53m) may improve the quality of results in somatic BRCAm identification and interpretation of the ‘second hit’ event, i.e., loss of heterozygosity (LOH). A total of 237 patients with HGSOC underwent tBRCA/TP53m testing. The ratio of allelic fractions (AFs) for tBRCA/TP53m was calculated to estimate the proportion of cells carrying BRCAm and to infer LOH. Among the 142/237 gBRCA results, 16.2% demonstrated a pathogenic/deleterious variant (DEL) gBRCA1/2m. Among the 195 contributive tumor samples, 43 DEL of tBRCAm (22.1%) were identified (23 gBRCAm and 20 sBRCAm) with LOH identified in 37/41 conclusive samples. The median AF of TP53m was 0.52 (0.01–0.93), confirming huge variability in tumor cellularity. Initially, three samples were considered as wild type with <10% cellularity. However, additional testing detected a very low AF (<0.05) in both BRCA1/2m and TP53m, thus reidentifying them as sBRCA1/2m. Combined tBRCA/TP53m testing is rapid, sensitive, and identifies somatic and germline BRCA1/2m. AF TP53m is essential for interpreting sBRCA1/2m in low-cellularity samples and provides indirect evidence for LOH as the ‘second hit’ of BRCA1/2-related tumorigenesis.</description><subject>Medical tests</subject><subject>Ovarian cancer</subject><subject>Tumor proteins</subject><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjr1PwzAQxT2ARCmM7JaY0_gzscc2AhqpUISyV1d_RK4aR4pT_n4sYGBAN9zvnd57OoQeKFlxrkkZTkNiggpKZU2u0IIKxgpCqvoG3aZ0IoRxJvUCvTXjcAzRWdxdhnEqNpAyt5uPZk1LVrYYYpbdu-SZXy8zzGGMuHNpDrHHIeL9J0wBIm4gGjfdoWsP5-Tuf_cSdc9PXbMtdvuXtlnvir6qVVFZCYY7rizTTJnvJw1hHiouDat4DWCZEGCOygoORntFgRpPKPFCS8KX6PGntoezO4Tox3kCM4RkDutaaiqZ5iq7Vv-48lg3BDNG50O-_wl8AQkBWns</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Borcoman, Edith</creator><creator>Santana dos Santos, Elizabeth</creator><creator>Genestie, Catherine</creator><creator>Pautier, Patricia</creator><creator>Lacroix, Ludovic</creator><creator>Caputo, Sandrine M</creator><creator>Cabaret, Odile</creator><creator>Guillaud-Bataille, Marine</creator><creator>Michels, Judith</creator><creator>Auguste, Aurelie</creator><creator>Leary, Alexandra</creator><creator>Rouleau, Etienne</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20230701</creationdate><title>Combined Tumor-Based IBRCA1/2/I and ITP53/I Mutation Testing in Ovarian Cancer</title><author>Borcoman, Edith ; Santana dos Santos, Elizabeth ; Genestie, Catherine ; Pautier, Patricia ; Lacroix, Ludovic ; Caputo, Sandrine M ; Cabaret, Odile ; Guillaud-Bataille, Marine ; Michels, Judith ; Auguste, Aurelie ; Leary, Alexandra ; Rouleau, Etienne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g678-6d5ac3e38d2928c41157c02fa635c2637aad244acb8d43ac9f81a1cf010f49503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Medical tests</topic><topic>Ovarian cancer</topic><topic>Tumor proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borcoman, Edith</creatorcontrib><creatorcontrib>Santana dos Santos, Elizabeth</creatorcontrib><creatorcontrib>Genestie, Catherine</creatorcontrib><creatorcontrib>Pautier, Patricia</creatorcontrib><creatorcontrib>Lacroix, Ludovic</creatorcontrib><creatorcontrib>Caputo, Sandrine M</creatorcontrib><creatorcontrib>Cabaret, Odile</creatorcontrib><creatorcontrib>Guillaud-Bataille, Marine</creatorcontrib><creatorcontrib>Michels, Judith</creatorcontrib><creatorcontrib>Auguste, Aurelie</creatorcontrib><creatorcontrib>Leary, Alexandra</creatorcontrib><creatorcontrib>Rouleau, Etienne</creatorcontrib><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borcoman, Edith</au><au>Santana dos Santos, Elizabeth</au><au>Genestie, Catherine</au><au>Pautier, Patricia</au><au>Lacroix, Ludovic</au><au>Caputo, Sandrine M</au><au>Cabaret, Odile</au><au>Guillaud-Bataille, Marine</au><au>Michels, Judith</au><au>Auguste, Aurelie</au><au>Leary, Alexandra</au><au>Rouleau, Etienne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined Tumor-Based IBRCA1/2/I and ITP53/I Mutation Testing in Ovarian Cancer</atitle><jtitle>International journal of molecular sciences</jtitle><date>2023-07-01</date><risdate>2023</risdate><volume>24</volume><issue>14</issue><issn>1422-0067</issn><abstract>Somatic/germline BRCA1/2 mutations (m)/(likely) pathogenic variants (PV) (s/gBRCAm) remain the best predictive biomarker for PARP inhibitor efficacy. As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic TP53m, combined tumor-based BRCA1/2 (tBRCA) and TP53 mutation testing (tBRCA/TP53m) may improve the quality of results in somatic BRCAm identification and interpretation of the ‘second hit’ event, i.e., loss of heterozygosity (LOH). A total of 237 patients with HGSOC underwent tBRCA/TP53m testing. The ratio of allelic fractions (AFs) for tBRCA/TP53m was calculated to estimate the proportion of cells carrying BRCAm and to infer LOH. Among the 142/237 gBRCA results, 16.2% demonstrated a pathogenic/deleterious variant (DEL) gBRCA1/2m. Among the 195 contributive tumor samples, 43 DEL of tBRCAm (22.1%) were identified (23 gBRCAm and 20 sBRCAm) with LOH identified in 37/41 conclusive samples. The median AF of TP53m was 0.52 (0.01–0.93), confirming huge variability in tumor cellularity. Initially, three samples were considered as wild type with <10% cellularity. However, additional testing detected a very low AF (<0.05) in both BRCA1/2m and TP53m, thus reidentifying them as sBRCA1/2m. Combined tBRCA/TP53m testing is rapid, sensitive, and identifies somatic and germline BRCA1/2m. AF TP53m is essential for interpreting sBRCA1/2m in low-cellularity samples and provides indirect evidence for LOH as the ‘second hit’ of BRCA1/2-related tumorigenesis.</abstract><pub>MDPI AG</pub><doi>10.3390/ijms241411570</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2023-07, Vol.24 (14) |
| issn | 1422-0067 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A759152938 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Medical tests Ovarian cancer Tumor proteins |
| title | Combined Tumor-Based IBRCA1/2/I and ITP53/I Mutation Testing in Ovarian Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T20%3A58%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20Tumor-Based%20IBRCA1/2/I%20and%20ITP53/I%20Mutation%20Testing%20in%20Ovarian%20Cancer&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Borcoman,%20Edith&rft.date=2023-07-01&rft.volume=24&rft.issue=14&rft.issn=1422-0067&rft_id=info:doi/10.3390/ijms241411570&rft_dat=%3Cgale%3EA759152938%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A759152938&rfr_iscdi=true |